PuriCore plc (LON:PURI)‘s stock had its “corporate” rating reaffirmed by N+1 Singer in a research report issued to clients and investors on Tuesday.

PuriCore plc (LON:PURI) opened at 25.021 on Tuesday. The stock’s market capitalization is GBX 12.54 million. The company has a 50 day moving average of GBX 20.60 and a 200-day moving average of GBX 22.74. PuriCore plc has a 12-month low of GBX 16.90 and a 12-month high of GBX 28.78.

PuriCore plc Company Profile

PuriCore Plc is a biopharmaceutical company engaged in leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company is also engaged in development of small molecule therapies in inflammatory diseases with application in dermatology, ophthalmology and rare diseases, and also for applicability across various other diseases.

Receive News & Ratings for PuriCore plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PuriCore plc and related companies with MarketBeat.com's FREE daily email newsletter.